Some hypotheses have been developed, such as T regulatory cell expansion and T cell exhaustion; however, the prevalence, the natural history, and the predictive factors of hyperprogression in patients with cancer treated by anti-PD-1/PD-L1 remain unknown [127]. The gene discussed is CD274; the disease is cancer.